Oregon Public Employees Retirement Fund Sells 6,500 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Oregon Public Employees Retirement Fund lessened its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 14.4% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 38,500 shares of the company's stock after selling 6,500 shares during the period. Oregon Public Employees Retirement Fund's holdings in Hims & Hers Health were worth $1,138,000 as of its most recent SEC filing.

Other institutional investors have also recently made changes to their positions in the company. Raymond James Financial Inc. bought a new stake in shares of Hims & Hers Health in the 4th quarter valued at about $18,048,000. O Shaughnessy Asset Management LLC bought a new stake in shares of Hims & Hers Health during the 4th quarter valued at about $208,000. Commonwealth Equity Services LLC boosted its position in shares of Hims & Hers Health by 111.6% during the 4th quarter. Commonwealth Equity Services LLC now owns 58,894 shares of the company's stock valued at $1,424,000 after purchasing an additional 31,062 shares in the last quarter. PNC Financial Services Group Inc. boosted its position in shares of Hims & Hers Health by 51.9% during the 4th quarter. PNC Financial Services Group Inc. now owns 17,225 shares of the company's stock valued at $417,000 after purchasing an additional 5,885 shares in the last quarter. Finally, Amundi boosted its position in shares of Hims & Hers Health by 49.1% during the 4th quarter. Amundi now owns 12,741 shares of the company's stock valued at $328,000 after purchasing an additional 4,197 shares in the last quarter. Institutional investors own 63.52% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently commented on the company. UBS Group set a $30.00 target price on Hims & Hers Health in a research report on Monday, June 23rd. Bank of America upped their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company an "underperform" rating in a research report on Tuesday, April 29th. Morgan Stanley restated an "equal weight" rating and set a $40.00 target price on shares of Hims & Hers Health in a research report on Wednesday, June 11th. Truist Financial set a $45.00 target price on Hims & Hers Health in a research report on Tuesday, June 24th. Finally, Wall Street Zen upgraded Hims & Hers Health from a "hold" rating to a "buy" rating in a research report on Sunday, June 15th. Three investment analysts have rated the stock with a sell rating, eight have assigned a hold rating and three have issued a buy rating to the company's stock. According to MarketBeat, Hims & Hers Health currently has a consensus rating of "Hold" and a consensus price target of $39.58.

Hims & Hers Health Trading Up 1.1%

HIMS stock traded up $0.54 during trading on Tuesday, reaching $48.96. 30,532,151 shares of the stock were exchanged, compared to its average volume of 23,585,292. The firm's 50 day moving average is $52.90 and its 200 day moving average is $40.59. Hims & Hers Health, Inc. has a twelve month low of $13.47 and a twelve month high of $72.98. The firm has a market cap of $10.96 billion, a P/E ratio of 70.96, a price-to-earnings-growth ratio of 1.78 and a beta of 2.02.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last issued its quarterly earnings data on Monday, May 5th. The company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.12 by $0.08. The firm had revenue of $586.01 million during the quarter, compared to the consensus estimate of $535.21 million. Hims & Hers Health had a return on equity of 22.75% and a net margin of 9.24%. The company's quarterly revenue was up 110.7% compared to the same quarter last year. During the same period in the prior year, the business posted $0.05 earnings per share. As a group, analysts predict that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Insider Transactions at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 11,581 shares of the stock in a transaction that occurred on Monday, July 7th. The stock was sold at an average price of $46.67, for a total value of $540,485.27. Following the completion of the sale, the chief financial officer directly owned 58,078 shares of the company's stock, valued at $2,710,500.26. This represents a 16.63% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Andrew Dudum sold 65,110 shares of the stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $59.22, for a total value of $3,855,814.20. Following the completion of the sale, the chief executive officer directly owned 95,105 shares of the company's stock, valued at approximately $5,632,118.10. This trade represents a 40.64% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 703,587 shares of company stock valued at $35,398,357. Corporate insiders own 17.71% of the company's stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.